Please assess the completion status of the following clinical trial:

Trial Title: Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 25 y/o~* No occurrence of intra- or post-operative cardiopulmonary arrest~* Not consuming drugs affecting atrial rhythm~* Having sinus rhythm before surgery~* Lack of paroxysmal atrial fibrillation history~* Only undergo heart valve surgery~* Lack of considerable heart ischemia needed atorvastatin use~* Routine cares in ward, post-operative ward, and intensive care unit were done~Exclusion Criteria:~* Lesser than 25 y/o~* History of atrial fibrillation~* History of taking anti-arrhythmic drugs~* History of implementing pacemakers~* Severe heart failure~* Renal failure~* Hepatic failure~* Severe pulmonary diseases~* Heart block or bradyarrhythmia~* Routine cares in ward, post-operative ward, and intensive care unit were not done~* Performing concomitant cardiac surgery except valve repair~* Having considerable heart ischemia needed atorvastatin use

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
- Control (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).